ValuEngine Upgrades Aerie Pharmaceuticals (AERI) to Buy

ValuEngine upgraded shares of Aerie Pharmaceuticals (NASDAQ:AERI) from a hold rating to a buy rating in a research note published on Monday, April 2nd.

Several other equities analysts also recently weighed in on AERI. Zacks Investment Research raised Aerie Pharmaceuticals from a strong sell rating to a hold rating in a research report on Monday, January 22nd. Seaport Global Securities started coverage on Aerie Pharmaceuticals in a research report on Friday, January 26th. They issued a buy rating and a $78.00 target price for the company. Canaccord Genuity set a $73.00 target price on Aerie Pharmaceuticals and gave the company a buy rating in a research report on Monday, December 18th. Cantor Fitzgerald set a $77.00 price objective on Aerie Pharmaceuticals and gave the stock a buy rating in a research report on Monday, December 18th. Finally, Mizuho reissued a buy rating and set a $87.00 price objective on shares of Aerie Pharmaceuticals in a research report on Monday, January 29th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Aerie Pharmaceuticals currently has a consensus rating of Buy and a consensus target price of $78.75.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ AERI traded down $0.65 during trading on Monday, hitting $54.50. 136,894 shares of the company were exchanged, compared to its average volume of 349,904. Aerie Pharmaceuticals has a 12-month low of $38.14 and a 12-month high of $66.60. The company has a quick ratio of 10.09, a current ratio of 10.09 and a debt-to-equity ratio of 0.91. The firm has a market cap of $2,097.07, a PE ratio of -16.17 and a beta of 0.95.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.21) by ($0.17). research analysts expect that Aerie Pharmaceuticals will post -3.62 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. QS Investors LLC purchased a new stake in Aerie Pharmaceuticals in the fourth quarter valued at approximately $125,000. Public Employees Retirement Association of Colorado purchased a new stake in Aerie Pharmaceuticals in the fourth quarter valued at approximately $176,000. Great West Life Assurance Co. Can lifted its stake in Aerie Pharmaceuticals by 65.0% in the third quarter. Great West Life Assurance Co. Can now owns 4,160 shares of the company’s stock valued at $204,000 after buying an additional 1,639 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. purchased a new stake in Aerie Pharmaceuticals in the third quarter valued at approximately $204,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Aerie Pharmaceuticals during the third quarter worth approximately $276,000. Institutional investors own 96.96% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally published by Week Herald and is owned by of Week Herald. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://weekherald.com/2018/04/19/aerie-pharmaceuticals-aeri-rating-increased-to-buy-at-valuengine.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply